GlassScriptPhysician profile
Madison Schwarz
NPI 1649042847
$2,900.39
in general payments reported to CMS, 2019-2025
21 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,034 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818 · Education: $82.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.30 |
| Education | $82.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $730.73 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $663.52 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $215.83 | 2024-2025 | |
| Csl Behring | $192.25 | 2024-2025 | Hizentra |
| Genentech USA, INC. | $164.97 | 2024-2025 | Xolair |
| Glaxosmithkline, LLC. | $163.83 | 2024-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $154.45 | 2024-2025 | |
| Octapharma USA, INC. | $126.28 | 2024 | Panzyga, Cutaquig |
| Paratek Pharmaceuticals, INC. | $102.26 | 2025 | Xhance |
| Grifols USA, LLC | $49.10 | 2025 | Xembify |
| Leo Pharma INC. | $48.40 | 2025 | Adbry |
| Lilly USA, LLC | $46.39 | 2025 | Ebglyss |
| Amgen INC. | $42.78 | 2024-2025 | Tezspire |
| Blueprint Medicines Corporation | $38.25 | 2024-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $33.50 | 2025 | Cuvitru |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $28.97 | 2025 | Orladeyo |
| Pharming Healthcare, INC. | $25.80 | 2025 | Ruconest |
| Pfizer INC. | $22.76 | 2025 | |
| Ascendis Pharma Endocrinology INC | $20.52 | 2025 | Yorvipath |
| Phadia US INC. | $15.60 | 2025 | Immunocap |
| Optinose US, INC. | $14.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Schwarz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.